Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Filippo Lagi

Showing results (31-40 of 81) with videos related to

Pageof 9
Sort By:
AIDS (London, England)|February 23, 2026
Changes in cardiovascular and metabolic risk scores after switching to DOR/3TC/TDF, DTG/3TC or BIC/FTC/TAF: results from a multicenter Italian cohortArturo Ciccullo, Valentina Iannone, Andrea Giacomelli, et al.
The Journal of Antimicrobial Chemotherapy|October 31, 2024
Comparing the long-term effectiveness and safety of dolutegravir/lamivudine versus bictegravir/emtricitabine/tenofovir alafenamide fumarate as first-line regimens: a real life multicentre cohortArturo Ciccullo, Gianmaria Baldin, Adriana Cervo, et al.
International Journal of STD & AIDS|August 6, 2024
Impact of rapid-antiretroviral therapy in a cohort of treatment-naïve migrants living with HIV in a high income settingSasha Trevisan, Giuseppe Gasparro, Seble Tekle Kiros, et al.
Allergy & Rhinology (Providence, R.I.)|December 7, 2020
Seasonal Allergic Rhinitis Symptoms in Relation to COVID-19Chiara Bruno, Luca Giovanni Locatello, Maria Cilona, et al.
Microbiology Spectrum|September 11, 2025
Teropavimab and zinlirvimab sensitivity in people living with multidrug-resistant HIV-1: data from the PRESTIGIO RegistryVincenzo Spagnuolo, Laura Galli, Jiani Li, et al.
Antiviral Therapy|October 3, 2018
A comparison between two dolutegravir-based two-drug regimens as switch strategies in a multicentre cohort of HIV-1-infected patientsArturo Ciccullo, Gianmaria Baldin, Amedeo Capetti, et al.
AIDS Research and Human Retroviruses|October 1, 2020
Overall Tolerability of Integrase Inhibitors in Clinical Practice: Results from a Multicenter Italian CohortArturo Ciccullo, Gianmaria Baldin, Vanni Borghi, et al.
Le Infezioni in Medicina|December 18, 2019
Single tablet regimen with abacavir/lamivudine/dolutegravir compared with two-drug regimen with lamivudine and dolutegravir as different strategies of simplification from a multicenter HIV cohort studyGianmaria Baldin, Arturo Ciccullo, Stefano Rusconi, et al.
AIDS Care|November 11, 2020
Long-term maintenance of virologic suppression in native and migrant HIV-1 naïve patients: an Italian cohort studyFilippo Lagi, Seble Tekle Kiros, Simona Di Giambenedetto, et al.
Journal of Medical Virology|October 8, 2023
Efficacy and tolerability of dolutegravir/lamivudine versus dolutegravir/rilpivirine in switching from a three-drug regimen based on nonnucleoside reverse transcriptase inhibitors: A retrospective cohort studyFilippo Lagi, Andrea Giacomelli, Vanni Borghi, et al.
Pageof 9

Showing results (31-40 of 81) with videos related to

Sort By:
Pageof 9
AIDS (London, England)|February 23, 2026
Changes in cardiovascular and metabolic risk scores after switching to DOR/3TC/TDF, DTG/3TC or BIC/FTC/TAF: results from a multicenter Italian cohortArturo Ciccullo, Valentina Iannone, Andrea Giacomelli, et al.
The Journal of Antimicrobial Chemotherapy|October 31, 2024
Comparing the long-term effectiveness and safety of dolutegravir/lamivudine versus bictegravir/emtricitabine/tenofovir alafenamide fumarate as first-line regimens: a real life multicentre cohortArturo Ciccullo, Gianmaria Baldin, Adriana Cervo, et al.
International Journal of STD & AIDS|August 6, 2024
Impact of rapid-antiretroviral therapy in a cohort of treatment-naïve migrants living with HIV in a high income settingSasha Trevisan, Giuseppe Gasparro, Seble Tekle Kiros, et al.
Allergy & Rhinology (Providence, R.I.)|December 7, 2020
Seasonal Allergic Rhinitis Symptoms in Relation to COVID-19Chiara Bruno, Luca Giovanni Locatello, Maria Cilona, et al.
Microbiology Spectrum|September 11, 2025
Teropavimab and zinlirvimab sensitivity in people living with multidrug-resistant HIV-1: data from the PRESTIGIO RegistryVincenzo Spagnuolo, Laura Galli, Jiani Li, et al.
Antiviral Therapy|October 3, 2018
A comparison between two dolutegravir-based two-drug regimens as switch strategies in a multicentre cohort of HIV-1-infected patientsArturo Ciccullo, Gianmaria Baldin, Amedeo Capetti, et al.
AIDS Research and Human Retroviruses|October 1, 2020
Overall Tolerability of Integrase Inhibitors in Clinical Practice: Results from a Multicenter Italian CohortArturo Ciccullo, Gianmaria Baldin, Vanni Borghi, et al.
Le Infezioni in Medicina|December 18, 2019
Single tablet regimen with abacavir/lamivudine/dolutegravir compared with two-drug regimen with lamivudine and dolutegravir as different strategies of simplification from a multicenter HIV cohort studyGianmaria Baldin, Arturo Ciccullo, Stefano Rusconi, et al.
AIDS Care|November 11, 2020
Long-term maintenance of virologic suppression in native and migrant HIV-1 naïve patients: an Italian cohort studyFilippo Lagi, Seble Tekle Kiros, Simona Di Giambenedetto, et al.
Journal of Medical Virology|October 8, 2023
Efficacy and tolerability of dolutegravir/lamivudine versus dolutegravir/rilpivirine in switching from a three-drug regimen based on nonnucleoside reverse transcriptase inhibitors: A retrospective cohort studyFilippo Lagi, Andrea Giacomelli, Vanni Borghi, et al.
Pageof 9